Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Prognostic factors in pterygopalatine and infratemporal fossa malignant tumours: A single institution experience.

PURPOSE: To elucidate the clinical characteristics of malignancies involving the pterygopalatine and infratemporal fossa and identify the outcome-related predictors.

METHODS: A retrospective review of the patients diagnosed with malignancies involving these spaces between 2006 and 2013 was conducted. We investigated the 5-year recurrence free survival, metastasis free survival and overall survival, and univariate and multivariate analysis were used to identify the outcome-related factors.

RESULTS: A total of 80 patients (46 male and 34 female) aged from 1 to 82 years were retrospectively analysed. The most frequent location for involved malignancies included the pterygopalatine fossa (n = 35, 43.8%), followed by the infratemporal fossa (n = 25, 31.2%) and the pterygopalatine and infratemporal fossa together (n = 20, 25%). In multivariate analysis, gender (HR: 2.59, 95% CI: 1.034-6.488, p = 0.042), margin status (HR: 6.158, 95% CI: 2.115-17.932, p = 0.001) and adjuvant radiotherapy (HR: 3.116, 95% CI: 1.057-9.191, p = 0.039) were predictors for the 5-year recurrence-free survival rate, and brain invasion (HR: 6.218, 95% CI: 1.375-28.115, p = 0.018) and surgical margin (HR: 21.961, 95% CI: 2.383-202.418, p = 0.006) were predictors for the 5-year overall survival rate.

CONCLUSION: These results indicate that malignancies involving the pterygopalatine and infratemporal fossa have a poor prognosis. Brain invasion is a dangerous sign for decreased survival. An ideal surgical margin is associated with a lower recurrence and higher survival rate. Adjuvant radiotherapy should be performed to achieve better local control.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app